Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases.
Ruben A G van EerdenNadine Leonie de BoerJob P van KootenChecca BakkersMichelle V DietzGeert-Jan M CreemersSanne M BuijsRamon BaxFemke M de ManRobin J LurvinkMarjolein DiepeveenAlexandra R M Brandt-KerkhofEsther van MeertenStijn L W KoolenIgnace H J T de HinghCornelis VerhoefRon H J MathijssenJacobus W A BurgerPublished in: The British journal of surgery (2023)
Administration of 75 mg intraperitoneal irinotecan concomitantly with systemic FOLFOX-bevacizumab was safe and well tolerated. Intraperitoneal SN-38 exposure was high and prolonged. As oncological outcomes were promising, intraperitoneal administration of irinotecan may be a good alternative to other, more invasive and costly treatment options. A phase II study is currently accruing.